CINGULATE INC (CING)
US17248W2044 - Common Stock
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company...
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
$10 Million of additional Capital Recently Raised Strengthening Balance Sheet...
Cingulate to Participate in Benzinga All Live Access Event
KANSAS CITY, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed...
Cingulate Announces Adjournment of Special Meeting
KANSAS CITY, Kan., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical company utilizing...
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
KANSAS CITY, Kan., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed...
CING Stock Earnings: Cingulate Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cingulate (NASDAQ:CING) just reported results for the second quarter of 2024.Ci...
CING Stock Earnings: Cingulate Misses EPS for Q2 2024
CING stock results show that Cingulate missed analyst estimates for earnings per share the second quarter of 2024.
Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 targeted in 1H 2025Licensing Activity Continues KANSAS CITY, Kan., Aug. 13, 2024 (GLOBE...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday and we have breakdowns of all the latest news affecting shares this morning!
Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
KANSAS CITY, Kan., June 28, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (the “Company”) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary...
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed...
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance
Twelve Required Registration Batches CompletedNew Drug Application Being Prepped for Submission KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) --...
CING Stock Earnings: Cingulate Beats EPS for Q1 2024
CING stock results show that Cingulate beat analyst estimates for earnings per share the first quarter of 2024.
CING Stock Earnings: Cingulate Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cingulate (NASDAQ:CING) just reported results for the first quarter of 2024.Cin...